Filtered By:
Specialty: Hematology
Drug: Clopidogrel

This page shows you your search results in order of relevance. This is page number 2.

Order by Relevance | Date

Total 70 results found since Jan 2013.

Individualized antithrombotic therapy.
Conclusion: An extensive therapeutic arsenal to interfere with clot formation requires an individualized approach considering the disease condition and co-morbidities of the patient, the anticoagulants' and patientcharacteristics. This review builds on and extens previous publications of the authors on this topic. PMID: 25597592 [PubMed - as supplied by publisher]
Source: Hamostaseologie - January 19, 2015 Category: Hematology Authors: Lüscher TF, Steffel J Tags: Hamostaseologie Source Type: research

Antiplatelet effects of clopidogrel and aspirin after interventional patent foramen ovale/ atrium septum defect closure.
In this study, we aimed to analyze the incidence of high on-treatment platelet reactivity (HTPR) to antiplatelet medication in patients undergoing PFO/ASD closure as well as clinical complications and thrombus formation on the occluder during six-month follow-up. This hypothesis generating pilot study was observed, which included 140 patients undergoing PFO/ASD closure. The primary endpoint was pharmacodynamic response to antiplatelet medication. A composite of death, myocardial infarction, bleeding, stroke and thrombus formation on the occluder during six-month follow-up was the secondary endpoint. HTPR to clopidogrel was...
Source: Platelets - February 14, 2016 Category: Hematology Tags: Platelets Source Type: research

Antithrombotic strategy and its relationship with outcomes in patients with atrial fibrillation and chronic coronary syndrome
This study aimed to explore antithrombotic strategy and its relationship with outcomes in patients with atrial fibrillation (AF) at high risk for stroke and chronic coronary syndrome (CCS) in real-world clinical practice. Patients with AF at high risk for stroke complicated with CCS from China Atrial Fibrillation Registry (CAFR) were enrolled. The patients were divided into non-antithrombotic (Non-AT) group, oral anticoagulants (OAC) group, antiplatelet therapy (APT) group (aspirin or clopidogrel), and dual antiplatelet therapy (DAPT) group (aspirin  + clopidogrel) according to their antithrombotic strategies at baseli...
Source: Journal of Thrombosis and Thrombolysis - October 22, 2021 Category: Hematology Source Type: research

Efficacy and safety of cilostazol based triple antiplatelet treatment versus dual antiplatelet treatment in patients undergoing coronary stent implantation: an updated meta-analysis of the randomized controlled trials
Abstract The aim of this study was to obtain best estimates of the efficacy and safety of cilostazol-based triple antiplatelet therapy (TAPT: aspirin, clopidogrel and cilostazol) compared with dual antiplatelet therapy (DAPT: aspirin and clopidogrel) in patients undergoing coronary stent implantation. We searched the literature to identify all randomized clinical trials examining efficacy and safety of TAPT versus DAPT in patients undergoing coronary stent implantation. Major efficacy outcomes were death, non-fatal myocardial infarction (MI), ischemic stroke and stent thrombosis (ST) and the safety outcome was bl...
Source: Journal of Thrombosis and Thrombolysis - January 1, 2015 Category: Hematology Source Type: research

Prior chronic clopidogrel therapy is associated with increased adverse events and early stent thrombosis.
Abstract Despite the growing use of clopidogrel, limited data exist regarding the prognostic significance of chronic clopidogrel therapy in patients sustaining acute coronary syndrome (ACS). Our aim was to determine whether patients sustaining ACS while on chronic clopidogrel therapy have a worse prognosis than clopidogrel-naïve patients. A total of 5,386 consecutive ACS patients were prospectively characterised and followed-up for 30 days. Of them, 680 (13 %) were treated with clopidogrel prior to the index ACS. Major adverse cardiovascular events (MACE) were defined as death, recurrent ACS, stroke and/or sten...
Source: Thrombosis and Haemostasis - October 8, 2015 Category: Hematology Authors: Asher E, Fefer P, Sabbag A, Herscovici R, Regev E, Mazin I, Shlomo N, Zahger D, Atar S, Hammerman H, Polak A, Beigel R, Matetzky S, PLATIS (Platelets and Thrombosis in Sheba) Study Group Tags: Thromb Haemost Source Type: research

An optimum prophylactic dose of prasugrel monotherapy may safely and effectively prevent the development of experimental thrombotic strokes
Myocardial infarction and stroke are two of the leading causes of death and disability worldwide [1,2]. Using a combination of aspirin and a platelet P2Y12 antagonist, several large clinical trials have definitively demonstrated the efficacy of dual antiplatelet therapies in preventing myocardial infarction, stroke or death in patients with acute coronary syndromes [3–8]. Dual antiplatelet therapy with aspirin and a thienopyridine-based P2Y12 antagonist (clopidogrel or prasugrel) has now become the standard of care of patients with acute coronary syndromes.
Source: Thrombosis Research - October 16, 2015 Category: Hematology Authors: Frederick A. Ofosu Source Type: research

A Rabbit Model of Cerebral Microembolic Signals for Translational Research: Preclinical Validation for Aspirin and Clopidogrel
ConclusionsOur study demonstrated the successful establishment of the MES model in rabbits, which may provide translational value for MES and ischemic stroke research.This article is protected by copyright. All rights reserved.
Source: Journal of Thrombosis and Haemostasis - April 30, 2016 Category: Hematology Authors: X Zhou, S Kurowski, W Wu, K Desai, L Chu, D E Gutstein, D Seiffert, X Wang Tags: Original Article ‐ Platelets Source Type: research

A Rabbit Model of Cerebral Microembolic Signals for Translational Research: Preclinical Validation for Aspirin and Clopidogrel.
CONCLUSIONS: Our study demonstrated the successful establishment of the MES model in rabbits, which may provide translational value for MES and ischemic stroke research. This article is protected by copyright. All rights reserved. PMID: 27262051 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - June 3, 2016 Category: Hematology Authors: Zhou X, Kurowski S, Wu W, Desai K, Chu L, Gutstein DE, Seiffert D, Wang X Tags: J Thromb Haemost Source Type: research

Clinical utility of remote platelet function measurement using P-selectin: assessment of aspirin, clopidogrel, and prasugrel and bleeding disorders.
Authors: Bath PM, May J, Heptinstall S Abstract Vascular diseases such as myocardial infarction and ischemic stroke are associated with increased platelet function whilst the risk of recurrence is reduced by antiplatelet agents such as aspirin, clopidogrel, and prasugrel. However, some patients exhibit high platelet reactivity, especially with clopidogrel. Existing platelet function tests may not be ideal in that they can be expensive, are often time consuming, and measurements must be made near to the patient and within a few hours of blood collection. Platelet activation leads to translocation of P-selectin from ...
Source: Platelets - April 20, 2018 Category: Hematology Tags: Platelets Source Type: research

Anticoagulation in Atherosclerotic Disease.
Abstract The prevention of atherothrombotic events is an essential therapeutic goal in the treatment of patients with arteriosclerotic diseases. After plaque rupture, a rapidly growing thrombus can lead to acute vascular occlusion and thus heart attack, stroke or limb ischaemia. The acute therapy combines anticoagulation and platelet inhibition. However, the only available therapy so far in the primary and secondary prevention of stable patients is the platelet inhibitors aspirin and clopidogrel. Despite the use of antiplatelet therapies, including aspirin and P2Y12-receptor antagonists, some patients with artery ...
Source: Hamostaseologie - October 17, 2018 Category: Hematology Authors: Al Said S, Bode C, Duerschmied D Tags: Hamostaseologie Source Type: research

A Study of Haemostatic Parameters in Patients with Philadelphia-Negative Myeloproliferative Neoplasms. Correlation with, Clinical, Laboratory, Molecular, and Treatment Characteristics
DiscussionGlobal assays such as thromboelastography are more useful than conventional hemostatic laboratory tests in depicting the hypercoagulable state in MPN. They may be useful in combination with other parameters such as the mutational status in identifying patients with MPN at higher risk for thrombosis and guide clinicians for the type of treatment (both cytoreductive and anticoagulants). Tests of platelet function assessment may help the clinicians adjust the type and dose of antiplatelet therapy.DisclosuresNo relevant conflicts of interest to declare.
Source: Blood - November 21, 2018 Category: Hematology Authors: Giannakopoulou, N., Politou, M., Diamantopoulos, P. T., Korakakis, D., Efstathopoulou, M., Kassi, T., Kontandreopoulou, C.-N., Zoi, K., Giannopoulos, A., Dimou, M., Panayiotidis, P., Viniou, N.-A. Tags: 634. Myeloproliferative Syndromes: Clinical: Poster III Source Type: research

Management of tandem occlusions in patients who receive rtPA
ConclusionThe use of GP2b3aI in the setting of tandem occlusions that required emergent stent placement post-rtPA appears safe and effective. Given the small sample size, these findings should be interpreted cautiously, and need to be confirmed in a larger patient population.
Source: Journal of Thrombosis and Thrombolysis - June 23, 2021 Category: Hematology Source Type: research

Clopidogrel monotherapy versus Aspirin monotherapy in patients with established cardiovascular disease: systematic review and meta-analysis
CONCLUSIONS: In patients with established cardiovascular disease, Clopidogrel was associated with a 17% relative-risk reduction for non-fatal MI, borderline decreased risk for MACE and similar risk for all-cause mortality, stroke and major bleeding compared to Aspirin.PMID:35577054 | DOI:10.1055/a-1853-2952
Source: Thrombosis and Haemostasis - May 16, 2022 Category: Hematology Authors: Panagiotis Tasoudis Ioannis Kyriakoulis Dimitrios Sagris Hans-Christoph Diener George Ntaios Source Type: research

Randomised, double-blind trial on the value of tapered discontinuation of clopidogrel maintenance therapy after drug-eluting stent implantation. Intracoronary Stenting and Antithrombotic Regimen: CAUTION in Discontinuing Clopidogrel Therapy - ISAR-CAUTION.
In conclusion, tapered discontinuation of chronic clopidogrel therapy is not superior to abrupt discontinuation regarding the primary endpoint in this study. However, the results must be interpreted in view of the premature termination of the trial and low event rates. PMID: 24633406 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - March 13, 2014 Category: Hematology Authors: Fiedler KA, Mehilli J, Kufner S, Schlichting A, Ibrahim T, Sibbing D, Ott I, Schunkert H, Laugwitz KL, Kastrati A, Schulz S Tags: Thromb Haemost Source Type: research